Moderna's 392% Year Meets Its First Real Down Day

Moderna shares fell as much as 7% on Aug. 24, 2026, trading at 137.50 (-5.26%) at 16:32 GMT after a 392% year-to-date advance, while BioNTech dropped 4.39% to 111.45 and Merck slipped 1.08% to 150.91.

Moderna Inc. (MRNA) spent Monday doing something it has barely done all year: falling hard. The stock was quoted at 137.50 at 16:32 GMT, down 5.26% from Friday's close of 145.13, after trading as low as 130.00 earlier in the session. At that low, the shares were down roughly 10.4% from the prior close — the kind of intraday air pocket that only shows up in names carrying a very large crowd.

And the crowd here is very large. Moderna has run 392% year to date, according to 24/7 Wall St, which put the single-session drawdown at 7% at its worst. By late morning the stock had clawed back a portion of that, but the session high of 145.50 sits barely above Friday's close — meaning every buyer from the opening bell onward is underwater.

A drawdown that looks smaller in percentage terms than it feels

Context matters when a stock is up nearly fivefold on the year. A 5.26% decline is a rounding error against a 392% advance; the arithmetic of compounding means the same dollar move that would gut a flat stock barely dents the chart of a vertical one. That is the bull case for calling Monday routine profit-taking: late August, thin volume, and a position that has become uncomfortably outsized in a lot of portfolios.

The bear case lives in the intraday range. A move from 145.13 down to 130.00 and back to 137.50 is not orderly rotation — it is a market discovering, briefly, that there is not much of a bid underneath. Momentum names typically break in exactly this pattern: a violent flush, a partial recovery that convinces dip-buyers the worst is over, then a slower grind lower as the marginal holder gives up. Whether Monday was the first or the last of those days is not knowable from one tape.

BioNTech and Merck show how far the selling travelled

The move was not isolated to Moderna. BioNTech (BNTX) fell 4.39% to 111.45 from a prior close of 116.57, and traded in a tight 110.52–114.56 band — a decline that tracked Moderna's direction without matching its violence. Merck (MRK) slipped 1.08% to 150.91 from 152.55.

That gradient is informative. If a company-specific problem had hit Moderna, BioNTech would not have moved in sympathy to the tune of more than four percent. If a sector-wide repricing were underway, Merck — a large, diversified, cash-generative pharmaceutical business — would be down considerably more than one percent. What the three prints together describe is a de-risking of the high-beta, high-narrative end of the sector, with the defensive end largely untouched. Investors sold what had gone up the most, which is the classic signature of profit-taking rather than a fundamental rethink.

The broader tape gave the selling somewhere to start

Monday was not a strong day for risk generally. The Nasdaq 100 tracker (QQQ) was down 0.69% at $708.50 against a prior close of $713.44, having traded as low as $702.70. The S&P 500 tracker (SPY) was off 0.14% at $764.62. The Dow tracker (DIA) was actually higher, up 0.30% at $533.83.

That split — growth down, industrials and value up — is the same rotation showing inside the biotech names. When money moves from long-duration, story-driven equities toward cash-flow-today businesses, a stock up 392% on the year is the first thing sold and a large-cap pharmaceutical is one of the last. Moderna's decline was roughly seven and a half times the Nasdaq 100's on the day, which is about what a high-beta name does on a mildly negative session.

What separates an exhale from an unwind

Moderna's decline was roughly seven and a half times the Nasdaq 100's on the day, which is about what a high-beta name does on a mildly negative session.

Three things distinguish the two, and none of them can be settled in a single session.

Whether the low holds. The 130.00 print is now a reference level. A subsequent session that takes it out on heavier turnover would suggest forced selling rather than discretionary trimming.
Whether the sympathy names stabilise. If BioNTech steadies while Moderna keeps sliding, the story has narrowed back to one company. If both keep falling together, the market is repricing a theme.
Whether Merck stays quiet. A large-cap pharma that is down only about one percent is telling you the sector's earnings base is not in question. That changes if the defensive names start participating in the decline.

For anyone who bought Moderna in the last few weeks, the mathematics are uncomfortable in a way the headline percentage hides. A stock that has multiplied several times over carries a shareholder base with wildly different cost bases: early holders are sitting on gains that a 5% day cannot touch, while recent entrants have no cushion at all. That asymmetry is what makes momentum unwinds self-reinforcing when they do arrive — the people with nothing to give back are the people who sell first and fastest.

The trade nobody wants to be last in

None of this argues that the 392% run was unjustified; the market does not hand out that kind of return without a reason, and one down day does not revoke it. But it does argue that the risk profile of owning the stock has changed. Buying a name after it has quintupled is a different proposition from buying it before, and the price action on Monday — a fifteen-point intraday range, a partial recovery, and no help from the broader tape — is a reminder that the exit in crowded positions is narrow.

The tell to watch is not the next headline out of the company. It is whether Moderna can put together a session that closes above where it opened, with BioNTech doing the same, while the Nasdaq is soft. Momentum that survives a weak market day is intact. Momentum that only works when everything else works is borrowed.

Key facts

MRNA price: 137.50, -5.26% (as of 16:32 GMT, Aug. 24, 2026)
Year-to-date run: +392% before Monday's decline
Sympathy moves: BNTX 111.45 (-4.39%); MRK 150.91 (-1.08%)
Intraday low: 130.00, roughly 10.4% below the prior close of 145.13

Frequently asked questions

How far did Moderna actually fall on Aug. 24, 2026?

Moderna traded at 137.50 as of 16:32 GMT, down 5.26% from the prior close of 145.13. At its intraday low of 130.00 the decline was steeper, roughly 10.4% below the prior close, which is where the widely quoted 7% drawdown figure comes from. The session high was 145.50, barely above Friday's close.

What was Moderna's year-to-date gain before the selloff?

Moderna had risen 392% year to date heading into the Aug. 24 session, according to 24/7 Wall St. Against a gain of that size, a single-session decline of just over five percent represents a small fraction of the advance, though it is a meaningful loss for anyone who bought the shares recently.

Did other vaccine and pharma stocks fall too?

Yes, but by less. BioNTech fell 4.39% to 111.45 from a prior close of 116.57, trading between 110.52 and 114.56. Merck slipped 1.08% to 150.91 from 152.55. The pattern suggests selling concentrated in high-momentum names rather than a broad repricing of pharmaceutical earnings.

Was the broader market down on the same day?

Partially. The Nasdaq 100 tracker QQQ fell 0.69% to $708.50 and the S&P 500 tracker SPY slipped 0.14% to $764.62, while the Dow tracker DIA rose 0.30% to $533.83. Growth stocks were weak and value stocks were firm, the same split visible inside the biotech names.

How can investors tell profit-taking from a genuine reversal?

Watch whether the intraday low of 130.00 holds on subsequent sessions, whether BioNTech stabilises or keeps falling alongside Moderna, and whether large-cap pharma such as Merck starts participating in the decline. Routine profit-taking stays confined to the highest-beta names; a genuine unwind spreads to the defensive end of the sector.

Why does a big year-to-date gain make a stock more fragile?

Because the shareholder base becomes split between long-term holders sitting on large gains and recent buyers with no cushion at all. Recent entrants tend to sell first and fastest in a decline, which is why momentum unwinds can become self-reinforcing once they begin, regardless of whether anything has changed at the company itself.

Sources

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips — 24/7 Wall St

Photo: Joshua Mayo · Pexels Licence — source